Cargando…
Institutional response to FDA warning on aprotinin and impact on outcomes
INTRODUCTION: New evidence of potential risks of aprotinin in 2006 generated public concern about a previously approved drug that was routinely used. In response, we assembled a team of experts within the institution to form guidelines for the appropriate use of aprotinin in cardiac surgery. We repo...
Autores principales: | Swaminathan, M, Stuart, M, Hughes, G C, Jaggers, J, Hill, S E, Milano, C A, Bennett-Guerrero, E, Stafford-Smith, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
EDIMES Edizioni Internazionali Srl
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484539/ https://www.ncbi.nlm.nih.gov/pubmed/23439283 |
Ejemplares similares
-
Anti-tumour Activity of Aprotinin
por: Latner, A. L., et al.
Publicado: (1974) -
Antifibrinolytic Agents: Aprotinin, and Desmopressin
por: Bajaj, Pramila
Publicado: (2009) -
Identification of an aprotinin antiviral domain
por: Pellegrini, Antonio, et al.
Publicado: (1994) -
Aprotinin and growth of Walker 256 carcinosarcoma in the rat.
por: Thomson, A. W., et al.
Publicado: (1977) -
Aprotinin—Drug against Respiratory Diseases
por: Ivachtchenko, Alexandre V., et al.
Publicado: (2023)